Dr. Paty on Patients With Rectal Cancer Ineligible for "Watch and Wait"

Video

In Partnership With:

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach.

Important factors to consider are tumor characteristics and the appearance of the rectal wall in the lymph nodes, Paty says. Tumors must be in a complete state of regression, which can be determined via cross-sectional imaging.

Tumors that are more difficult to eradicate are bulkier and larger in size are usually not fit for a "watch and wait" approach. Intermediate- and smaller-size tumors will likely have a higher cure rate via non-operative management; because they are smaller in size, it is easier to assess their response to treatment.

Patients with a lot of disease in the mesentery are also not appropriate candidates for "watch and wait," Paty says.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD